Bayer AG (BAYGn.DE)
89.43EUR
11:35am EDT
€2.08 (+2.38%)
€84.61
€87.83
€89.96
€87.74
2,688,204
2,080,847
€89.96
€60.41
About
Overall
| Beta: | 0.78 |
| Market Cap (Mil.): | €72,233.89 |
| Shares Outstanding (Mil.): | 826.95 |
| Dividend: | 1.90 |
| Yield (%): | 2.18 |
Financials
| BAYGn.DE | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 28.26 | 37.93 | 37.76 |
| EPS (TTM): | 3.09 | -- | -- |
| ROI: | 6.59 | 19.48 | 18.76 |
| ROE: | 12.89 | 20.17 | 19.59 |
European shares kept buoyant by data, earnings
LONDON, July 31 - European equities rose on Wednesday, kept buoyant by robust data out of the United States and Europe as well as strong earnings releases from major companies.
UPDATE 1-Bayer warns outlook seems ambitious as plastics weaken
* Shares indicated 2 pct lower (Adds details on new drugs, MaterialScience unit)
EU Commission clears way for Bayer acne pill sales in France
BRUSSELS, July 30 - The European Commission confirmed on Tuesday that the Bayer acne pill Diane 35 was safe for use, a seal of approval which will oblige France to allow sales of the product.
Analysis: Bayer immune to pharma's breakup bug?
FRANKFURT - Investors banking on Bayer to embrace a trend in the pharma sector to split off non-core units may be too far ahead of the curve.
Bayer starts clinical of drug for children with haemophilia
FRANKFURT, July 8 - Bayer AG said it had started a late stage clinical trial of its drug BAY 94-9027 for prophylaxis and treatment of bleeding in previously treated children with severe haemophilia A, it said in a statement on Monday. (Reporting by Jonathan Gould; Editing by Christoph Steitz)
BRIEF-Bayer's Nexavar submitted to EMA, FDA for thyroid cancer use
FRANKFURT, July 1 - Bayer AG : * Says sorafenib (nexavar) submitted to the ema and FDA for use in thyroid
Bayer cancer drug recommended in EU
LONDON, June xx - Experts at the European Medicines Agency have recommended approval of Bayer's drug Stivarga for the treatment of metastatic colorectal cancer.
Bayer rival Boehringer seeks wider use of anti-clotting pill
FRANKFURT - Boehringer Ingelheim has asked European regulators to approve a wider use of its anti-blood-clotting pill Pradaxa to include the treatment of deep vein thrombosis and pulmonary embolisms.
Europe shares dip as Chinese data hits miners
PARIS, June 10 - European stocks ended slightly lower on Monday as China's unexpectedly weak imports data prompted investors to dump cyclical miners and pick up defensive companies such as Deutsche Telekom and Bayer .
Bayer say VEGF Trap-Eye shows promise as mCNV treatment
FRANKFURT, June 6 - Bayer said on Thursday its drug VEGF Trap-Eye had demonstrated to improve visual acuity in a late-stage trial on patients suffering from myopic choroidal neovascularization (mCNV).
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: Finlabo SIM Spa
|
$10.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

